LY6D is mainly involved in lymphoid differentiation and cell surface activity, and the study showed that LY6D is significantly highly expressed in PAAD and is a valid predictor of PAAD, a result consistent with our study (Wang et al., 2020; Xu et al., 2021). Here, LY6D is linked to pancreatic adenocarcinoma.